Mosunetuzumab in Combination With Pirtobrutinib in Patients With Relapsed or Refractory Waldenstrom Macroglobulinemia (MPOWER)

NCT07548450 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

25

Enrollment

OTHER

Sponsor class

Conditions

Waldenstrom Macroglobulinemia

Interventions

DRUG: Pirtobrutinib
DRUG: Mosunetuzumab

Sponsor

University of Utah

Collaborators

[object Object]
[object Object]